Verified Nov 2026
Other
·
Princeton, New Jersey
·
Since 2012
CytoSorbents Corporation is a publicly traded medical device company headquartered in Princeton, New Jersey, with a founding year of 2012 and a reported workforce of 100 to 200 employees. It develops blood purification technologies for critical care and cardiac surgery, serving the medical sector. Its CytoSorb product line is designed to remove inflammatory mediators from blood in patients with conditions such as sepsis. In its most recent reported results, the company announced its second quarter 2026 financial results and regulatory update, a 2026 disclosure that outlined the FDA path for its DrugSorb-ATR product.
CytoSorbents Corporation at a glance
Revenue
37.1M
Employees
100-200
Founded
2012
Headquarters
Princeton, New Jersey
Ownership
Publicly traded (NASDAQ: CTSO)
Certifications
ISO 13485
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
STABILITY SIGNALS
Established & strong
14 years in operation (founded 2012).
Publicly listed; no distress event on record.
Holds ISO 13485 certification(s) per public sources.
Overview
CytoSorbents Corporation is a publicly traded medical device company headquartered in Princeton, New Jersey, with a founding year of 2012 and a reported workforce of 100 to 200 employees. It develops blood purification technologies for critical care and cardiac surgery, serving the medical sector. Its CytoSorb product line is designed to remove inflammatory mediators from blood in patients with conditions such as sepsis. In its most recent reported results, the company announced its second quarter 2026 financial results and regulatory update, a 2026 disclosure that outlined the FDA path for its DrugSorb-ATR product.
At a glance
Attribute | Detail |
|---|---|
Founded | 2012 |
Headquarters | Princeton, New Jersey |
Employees | 100-200 |
Revenue | 37.1M |
Ownership | Publicly traded (NASDAQ: CTSO) |
Certifications | ISO 13485 |
What CytoSorbents Corporation makes
The company holds ISO 13485 certification for its medical device quality management.
Certifications
CytoSorbents Corporation is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 13485 — sec.gov
Latest developments
2026-08-06 — CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update (prnewswire.com)
2026-06-25 — CytoSorbents outlines DrugSorb-ATR FDA path and 2026 metrics | CTSO 8-K Filing (stocktitan.net)
2026-05-13 — CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CytoSorbents Investor Relations (cytosorbents.com)
2026-05-13 — Cytosorbents Corp News and Press Releases | PR Newswire (prnewswire.com)
2026-03-25 — CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | CytoSorbents Investor Relations (cytosorbents.com)
2026-03-19 — CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 (prnewswire.com)
Facilities
CytoSorbents Corporation is headquartered in Princeton, New Jersey. Public sources also reference these locations:
Princeton, New Jersey — sec.gov
Company details
CytoSorbents trades on the public market under the ticker CTSO, with a reported revenue band of 37.1 million dollars. CytoSorbents Corporation was founded in 2012, has an estimated 100-200 employees, and is headquartered in Princeton, New Jersey. On the LightSource stability read it is rated "Established & strong": 14 years in operation (founded 2012). Publicly listed; no distress event on record. Holds ISO 13485 certification(s) per public sources.
Frequently asked questions
What does CytoSorbents Corporation do?
CytoSorbents Corporation is a publicly traded medical device company headquartered in Princeton, New Jersey, with a founding year of 2012 and a reported workforce of 100 to 200 employees. It develops blood purification technologies for critical care and cardiac surgery, serving the medical sector. Its CytoSorb product line is designed to remove inflammatory mediators from blood in patients with conditions such as sepsis. In its most recent reported results, the company announced its second quarter 2026 financial results and regulatory update, a 2026 disclosure that outlined the FDA path for its DrugSorb-ATR product.
Where is CytoSorbents Corporation headquartered?
CytoSorbents Corporation is headquartered in Princeton, New Jersey (305 College Rd E, Princeton, New Jersey, 08540-6608).
When was CytoSorbents Corporation founded?
CytoSorbents Corporation was founded in 2012.
How big is CytoSorbents Corporation?
CytoSorbents Corporation has an estimated 100-200 employees, with revenue in the 37.1M range.
Is CytoSorbents Corporation publicly traded?
Publicly traded (NASDAQ: CTSO). Public financial figures are drawn from its filings.
What certifications does CytoSorbents Corporation hold?
CytoSorbents Corporation lists ISO 13485 on its website. Confirm the certified scope for the specific plant producing your part.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile comes from a public-data sample of around 1,000 companies. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.